On 18 December 2024, the U.S. FDA approved ensartinib (X-396, brand name Ensacove, Xcovery Holdings, Inc.), an ALK inhibitor by Xcovery Holdings, for adults with locally advanced or metastatic ALK-positive NSCLC who have not received prior ALK inhibitor therapy [8]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.